Abstract
For a drug to produce its effect, it must be present in an appropriate concentration at the site of action. This concentration will be influenced by the dose, the rate and the amount of absorption, how the drug is distributed in the body, how it is metabolized and how rapidly it is excreted.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Alkjaersig N, Fletcher AP, De Ziegler D, Steingold KA, Meldrum DR, JuddHL(1988)Blood coagulation in postmenopausal women given estrogen treatment. Comparison of transdermal and oral administration. J Lab Clin Med 111:224–228
Baker V (1994) Alternatives to oral estrogen replacement. Obstet Gynecol Clin North Amer 21(2)271–297
Baracat E, Tufik S, Castelo A, Rodrigues de Lima G, Haidar M, Casoy J, Peloso U (1995)Comparative bioavailability of a matrix versus a reservoir transdermal estradiol patch in healthy postmenopausal women. Curr Ther Res 56(4)358–368
Barnes RD, Lobo RA (1987)Pharmacology of estrogens. In: Mishell DR Jr (ed)Menopause. Physiology and Pharmacology. Chicago, Year Book Medical Publishers, pp 301–315
Borg ML, Gimona A, Renoux A, Douin MJ, Djebbar F, Panis-Rouzier R (1995). Pharmacokinetics of estradiol and estrone following repeated administration of Menorest, a new estrogen transdermal delivery system, in menopausal women. Clin Drug Invest 10(2)96–103
Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM et al(1987)Cardiovascular mortality and non contraceptive use of estrogen in women: results from the lipid research clinics program follow-up study. Circulation: 75:1102–1109
Buster JE (1985) Estrogen metabolism. In: Sciarra JJ (ed)Gynecology and Obstetrics. Philadelphia, Harper and Row
Cagnacci A, Soldani R, Carriero PL, Pauletti AM, Fioretti P, Melis GB (1992)Effects of low doses of transdermal 17 j3-estradiol on carbohydrate metabolism in postmenopausal women. J Clin Endocrinol Metab 74:1396–1400
Cheang A, Sitruk-Ware R, Utian W(1993)A risk-benefit appraisal of transdermal estradiol therapy. Drug Safety 9(5)365–379
Cheang A, Sitruk-Ware R, Samsioe G(1994)Transdermal oestradiol and cardiovascular risk factors. 101:571–581
Chetkowski RJ, Meldrum DR, Steingold KA, Randle R, Lu JK, Eggena P, Hershman JM, Alkjaersig NK, Fletcher AP, Judd HL(1986)Biologic effects of transdermal estradiol. N Engl J Med 314:1615–1620
Christiansen C, Christensen MS, McNair P, Hagen C, Stocklund KE, Transbol I(1980)Prevention of early postmenopausal bone loss: a controlled 2-year study in 315 normal females. Eur J Clin Invest 10:273–279
Clarck JH, Peck EJ Jr(1979)Female Sex Steroids. Receptors and Function. Monographs on Endocrinology. New York, SpringerClisham P, Cedars MI, Greendale G, Fu YS, Gambone J, Judd H (1992) Long-term transdermal estradiol therapy: effects on endometrial histology and bleeding patterns.Obstet Gynecol 79:196–201
Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH (1987)Menopause and the risk of coronary heart disease in women. N EngI J Med 316:1105–1110
Collins P, Rosano GMC, Jiang C, Lindsay D, Sarrel PM, Poole-Wilson PA(1993)Cardiovascular protection by estrogen, a calcium antagonist effect. 341:1264–1265
Crook D, Cust MP, Gangar KF, Worthington M, Hillard TC, Stevenson JC, Whitehead MI, Wynn V(1992)Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 166:950–955
De Lignieres B, Basdevant A, Thomas G, Thalabard JC, Mercier-Bodard C, Conard J, Guyenne TT, Mairon N, Corvol P, Guy-Grand B, Mauvais-Jarvis P, Sitruk-Ware R(1986)Biological effects of estradiol 17 f3 in postmenopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab 62:536–541
Erkkola RU, Hirvonen EJ, Juntunen K, Saastamoinen JA, Tuimala RJ, Rinne R, Paakkari I(1995)Comparison of transdermal to oral hormone replacement therapy. Eur Menopause J 2:21–27
Ettinger B, Genant HK, Steiger P, Madvig P(1992)Low dosage micronised 17 f3 estradiol prevents bone loss in postmenopausal women. Am J Obstet Gynecol 166:479–488
Field CS, Ory SJ, Wahner HW, Hermann RR, Judd HL, Riggs BL(1992)Preventive effects of trans dermal 17 f3-estradiol on osteoporotic changes after surgical menopause: a two year placebo-controlled trial. Am J Obstet Gynecol 168:114–121
Foidart JM, Dombrowicz N, De Lignieres B (1991) Urinary excretion of prostacylin and thromboxane metabolites in postmenopausal women treated with percutaneous estradiol (Oestrogel) or conjugated estrogens (Premarin): In: Dusitsin N et al. (eds)Physiological hormone replacement therapy. Carnforth Parthenon, pp 99–107
Godsland IF, Gangar K, Walton C, Cust MP, Whitehead MI, Wynn V, Stevenson JC(1993)Insulin resistance, secretion and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 42:846–853
Goebelsmann U, Mashchak A, Mishell DR Jr(1985)Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol. Am J Obstet Gynecol 151:868–877
Gurpide E (1978) Metabolic influences of the action of estrogens: therapeutic implications. Pediatrics (Suppl) 62:1114–1120
Hassager C, Jensen SB, Christiansen C(1994)Non-responders to hormone replacement therapy for the prevention of postmenopausal bone loss: Do they exist?Osteoporosis Int 4:36–41
Helgason S (1982)Estrogen replacement therapy after the menopause. Estrogenicity and metabolic effects. Acta Obstet Gynecol Scand (Suppl) 107:5–29
Henzl MR (1986) Contraceptive hormones and their clinical use. In: Yen SSE, Jaffe RB (eds)Reproductive Endocrinology 2nd edition. Saunders, Philadelphia, pp 643–682
Hillard TC, Whitcroft SJ, March MS, Ellerington MC, Lees B, Whitehead MJ, Stevenson JC (1994)Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss. Osteoporosis Int 4:341–348
Holdright DR, Sullivan AK, Wright CA, Sparrow JL, Cunningham D, Fox KM(1995)Acute effect of estrogen replacement therapy on treadmill performance in postmenopausal women with coronary artery disease. Eur Heart J 16:1566–1570
Hulley S, Grady D, Bush T, Furberg C, Herrington 0, Riggs B, Vittinghoff E(1998)Heart and estrogen/progestin replacement study (HERS) research group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 208:605–613
James 1M (1996) Pharmacological principles of drug action. In: Ginsburg J (ed)Drug therapy in Reproductive Endocrinology. London, Arnold, pp 1–20
Jensen J, Christiansen C(1988)Effects of smoking on serum lipoproteins and bone mineral content during postmenopausal hormone replacement therapy. Am J Obstet Gynecol 159:820–825
Jensen J, Riis BJ, Strom V, Nilas L, Christiansen C(1987)Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women. Am J Obstet Gynecol 156:66–71
Kiel DP, Baron JA, Anderson 11, Hannan MT, Felson DT (1992)Smoking eliminates the protective effect of oral estrogens on the risk for hip fracture among women. Ann Intern Med 116:716–721
King RJB, Dyer G, Collins WP (1980)Intracellular estradiol, estrone and estrogen receptor levels in endometria from postmenopausal women receiving estrogens and progestins. J Steroid Biochem 13:377–382
Lobo RA, March CM, Goebelsmann V, Krauss RM, Mishell DR Jr (1980)Subdermal estradiol pellets following hysterectomy and oophorectomy. Am J Obstet Gynecol 138:714–719
MacIntyre I, Stevenson JC, Whitehead MI, Wimalawansa SJ, Banks LM, Healy MJR (1988)Calcitonin for prevention of postmenopausal bone loss. Lancet 1:900–902
Marty JP, James M, Hajo N, Wepierre J (1980)Percutaneous absorption of oestradiol and progesterone: pharmacokinetic studies. In: Mauvais-Jarvis P, Vickers CFH, Wepierre J (eds) Percutaneous absorption of steroids. London, Academic Press, pp 205–218
Mashchak CA, Lobo RA, Dozono-Takano R (1982)Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol 144:511–518
Mishell DR Jr, Moore DE, Roy S, Brenner PF, Page MA (1978)Clinical performance and endocrine profiles with contraceptive vaginal rings containing a combination of estradiol and d-norgestrel. Am J Obstet Gynecol 130:55–62
Pang SC, Greendale GA, Cedars MI, Cambone JC, Lozano K, Eggena P, Judd HL(1993)Long term effects of transdermal estradiol with and without medroxyprogesterone acetate. Fertil Steril 59:76–82
Perez-Gutthann S, Garcia-Rodriguez LA, Duque-Oliart A, Castellsague- Pique J (1995)HRT and the risk of venous thromboembolic event. Pharmacoepidemiol Drug Safety 4(Suppl 1 Abstract 118):S53
Powers MS, Schenkel L, Darley PE, Good WR, Balestra JC, Place VA(1985)Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17 j3-estradiol: comparison with conventional oral estrogen used for hormone replacement. Am J Obstet Gynecol 152:1099–1106
Reginster JY, Sarlet N, Deroisy R,Albert A, Gaspard U, Franchimont P(1992)Minimal levels of serum estradiol prevent postmenopausal bone loss. Calcif Tissue Int 51:340–343
Rigg LA, Hermann H, Yen SSC( 1978)Absorption of estrogens from vaginal creams. N Engl J Med 298:195–197
Rosano GMC, Sarrel PM, Poole-Wilson PA, Collins P(1993)Beneficial effects of estrogen on exercise-induced myocardial ischemia in women with coronary artery disease. Lancet 342:133–136
Setnikar I, Rovati LC, Thebault 11, Guillaume M, Mignot A, Renoux A, Gualano V(1997)Pharmacokinetics of estradiol and estrone during application of three strengths of an estradiol transdermal patch with active matrix. Arzneim ForschlDrug Res 47(II)n7:859–865
Sitruk-Ware R, Ibarra de Palacios P(1989)Estrogen replacement therapy and cardiovascular disease in postmenopausal women. A review. Maturitas 11:259–274
Sitruk-Ware R, De Lignieres B, Basdevant A, Mauvais-Jarvis P (1980) Absorption of percutaneous oestradiol in postmenopausal women. Maturitas 2:207–211
Stampfer MJ, Colditz GA(1991)Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Prev Med 20:47–63
Stanczyk FZ, Shoupe D, Nunez V, Macias-Gonzales P, Vijod MA, Lobo A(1988)A randomized comparison of non-oral estradiol delivery in postmenopausal women. Am J Obstet Gynecol 159:1540–1546
Steingold KA, Cefalu W, Pardrige W, Judd HL, Chaudhuri G(1986) Enhanced hepatic extraction of estrogens used for replacement therapy. J Clin Endocrinol Metab 62:761–766
Studd JWW, McCarthy K, Zamblera D, Burger HG, Silberberg S, Wren B, Dain MP, Le Lann L, Vandepol C(1995)Efficacy and tolerance of Menorest compared to Premarin in the treatment of postmenopausal women.A randomised, multicentre, double-blind, double-dummy study.Maturitas 22:105–114
The writing group for the PEPI trial. (1995)Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Intervention (PEPI) Trial.JAMA 273:199–208
The writing group for the PEPI Trial (1996)Effects of hormone replacement therapy on endometrial histology in postmenopausal women.JAMA 275:370–375
Von Schoultz B (1988) Potency of different estrogen preparations. In: Studd JWW, Whitehead MI (eds)The Menopause. Oxford, Blackwell Scientific, pp 130–137
Whitehead MI, Townsend PT, Kitchin Y (1980)Plasma steroid and protein hormone profiles in postmenopausal women following topical administration of estradiol 17/3. In: Mauvais-Jarvis P, Vickers CFH, Wepierre J (eds)Percutaneous Absorption of Steroids. London, Academic Press, pp 231–248
Wiseman LR, McTavish D(1994)Transdermal Estradiol/Norethisterone. Drugs and Aging 4:238–256
Woodruff JD, Pickar J (1994)Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxy progesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 70:1213–1223
Wynn V, Adams PW, Godsland I, Melrose J, Niththyananthan R, Oakley NW, Seed M(1979)Comparison of effects of different combined oral contraceptive formulations on carbohydrate and lipid metabolism. Lancet 1:1045–1049
Yen SSC, Martin PL, Burnier AM, Czekala NM, Greney MO Jr, Callantine MR(1975)Circulating estradiol, estrone and gonadotropin levels following the administration of orally active 17 f3-estradiol in postmenopausal women. J Clin Endocrinol Metab 40:518–520
Ylikorkala 0, Orpana A, Puolakka I, Pyoriila T, Viinikka L(1995) Postmenopausal hormonal replacement decreases plasma levels of endothelin I.J Clin Endocrinol Metab 80:3384–3387
Rights and permissions
Copyright information
© 1999 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Sitruk-Ware, R. (1999). Pharmacology of Different Administration Routes - Oral vs Transdermal. In: Estrogens and Antiestrogens II. Handbook of Experimental Pharmacology, vol 135 / 2. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60107-1_14
Download citation
DOI: https://doi.org/10.1007/978-3-642-60107-1_14
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-64261-6
Online ISBN: 978-3-642-60107-1
eBook Packages: Springer Book Archive